Growth Hormone Deficiency Market Research Report Forecast to 2027

List of Tables

Market Overview

The Growth Hormone Deficiency Market is anticipated to register a healthy CAGR of 4.19% during the review period.

The growth hormone deficiency market is encountering critical growth driven by headways in analysis, expanding mindfulness, and extending treatment choices. Developing acknowledgment of the effect of growth hormone deficiency on wellbeing, combined with progressing research and improvement endeavors, positions this market for proceeded with extension soon.

The growth of the Growth Hormone Deficiency Market is supposed to be driven by the rising number of people experiencing growth hormone deficiency (GHD), rising mindfulness in regard to the adequacy of GH alongside clinical preliminaries zeroed in on the security and viability of GHD, and the changing way of life alongside the developing predominance of hereditary problems.

As per the distributed article in NCBI in Walk 2017, the assessed commonness of GHD is roughly 2-3 out of 10,000 populaces. GHD is brought about by primary pituitary sickness or cranial illumination and happens with regards to extra elements of hypopituitarism. Pituitary adenomas are reported to cause grown-up beginning GHD followed by craniopharyngiomas, which represents roughly 57% of cases. What's more, adolescence beginning growth hormone deficiency (CO-GHD) is one of the perplexing endocrine circumstances that might have an effect over the course of life, beginning in youth, and going on till adulthood. Most of the CO-GH is reported to be intrinsic. The fundamental co-morbidities and side effects of GHD in grown-ups and kids are heftiness, diabetes mellitus, hypertension, cerebrovascular illnesses, cardiovascular sicknesses, and liver sicknesses. This rising bleakness of GH sickness in the two kids and grown-ups is supposed to drive the growth of the growth hormone deficiency market.

Market Segmentation

Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and more brands are included in the Growth Hormone Deficiency Market segmentation based on brand.

The market is divided into categories according to the application: prader-willi syndrome, turner syndrome, adult growth hormone deficit, small for gestational age, idiopathic short stature, and others.

The subcutaneous, intramuscular, and intravenous routes of delivery are used to segment the growth hormone deficiency market. Clinics, e-commerce websites, hospital pharmacies, and retail pharmacies make up the market's distribution channels.

Regional Insights

The Americas growth hormone deficiency market represented the biggest market share in 2022. Key elements ascribed to its huge offer incorporate created medical services framework, expanding mechanical headway, and the presence of many market players in the region.

Europe growth hormone deficiency market represented the second-biggest market share because of developing predominance of GHD people, and the rising attention to treatment.

The Asia-Pacific growth hormone deficiency market is supposed to be the quickest developing from 2023 to 2027 because of developing progression in treatment, expanding assets in research exercises, and rising pervasiveness of GHD.

Major Players

Key Companies in the Growth Hormone Deficiency market includes Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China).

Product Code: MRFR/HC/8950-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCE OF GROWTH HORMONE DEFICIENCY
- 4.2.2 RISING NUMBER OF CLINICAL TRIAL FOR GH DEFICIENCY
- 4.2.3 GOVERNMENT INITIATIVES FOR GHD
- 4.2.4 INCREASING NUMBER OF PRODUCT LAUNCH AND STRATEGIC COLLABORATIONS AMONG MARKET PLAYERS
4.3 RESTRAINTS
- 4.3.1 HIGH COST OF GHD TREATMENT
- 4.3.2 INCREASING COUNTERFEIT PRODUCTS FOR GHD TREATMENT
4.4 OPPORTUNITIES
- 4.4.1 STRONG PIPELINE OF HORMONAL DRUGS AND EASY AVAILABILITY OF PHARMA DRUGS ON E-COMMERCE PLATFORMS
4.5 CLINICAL TRIALS ANALYSIS
4.6 MEGATRENDS
- 4.6.1 ADVENT OF LONG-ACTING RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
- 4.6.2 USE OF HGH AS PERFORMANCE ENHANCERS AND ANTI-AGING AGENTS
- 4.6.3 PRODUCTS UNDER DEVELOPMENT
4.7 MACROECONOMIC INDICATORS
4.8 GOVERNMENT REGULATIONS AND NEW TREATMENT SCHEMES
4.9 LONG ACTING GROWTH HORMONES (LAGH)
- 4.9.1 OVERVIEW
- 4.9.2 DEVELOPMENT
- 4.9.3 UPCOMING PRODUCTS
- 4.9.4 TRENDS

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 RESEARCH AND DEVELOPMENT
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION
- 5.1.4 MARKETING AND SALES
- 5.1.5 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 RIVALRY
5.3 IMPACT OF COVID-19
- 5.3.1 OVERVIEW
- 5.3.2 IMPACT ON SUPPLY CHAIN
- 5.3.3 IMPACT ON PRODUCTION
5.4 EPIDEMIOLOGY DATA ON TYPE OF GROWTH HORMONE DEFICIENCY DISEASES (2022)

6 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY BRAND

6.1 OVERVIEW
6.2 NORDITROPIN
6.3 GENOTROPIN
6.4 HUMATROPE
6.5 SAIZEN
6.6 OMNITROPE

7 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 PAEDIATRIC GROWTH HORMONE DEFICIENCY
7.3 IDIOPATHIC SHORT STATURE
7.4 SMALL FOR GESTATIONAL AGE
7.5 TURNER SYNDROME
7.6 ADULT GROWTH HORMONE DEFICIENCY
7.7 PRADER-WILLI SYNDROME

8 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY ROUTE OF ADMINISTRATION

8.1 OVERVIEW
8.2 SUBCUTANEOUS
8.3 INTRAMUSCULAR
8.4 INTRAVENOUS

9 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 RETAIL PHARMACIES
9.4 CLINICS
9.5 E-COMMERCE WEBSITES

10 GLOBAL GROWTH HORMONE DEFICIENCY MARKET, BY REGION

10.1 OVERVIEW
10.2 AMERICAS
- 10.2.1 NORTH AMERICA
  - 10.2.1.1 US
  - 10.2.1.2 CANADA
- 10.2.2 LATIN AMERICA
10.3 EUROPE
- 10.3.1 WESTERN EUROPE
  - 10.3.1.1 GERMANY
  - 10.3.1.2 FRANCE
  - 10.3.1.3 UK
  - 10.3.1.4 ITALY
  - 10.3.1.5 SPAIN
  - 10.3.1.6 REST OF WESTERN EUROPE
- 10.3.2 EASTERN EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 MIDDLE EAST AND AFRICA
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 GLOBAL GROWTH HORMONE DEFICIENCY MARKET SHARE ANALYSIS (2019)
11.3 COMPETITIVE BENCHMARKING
11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
11.5 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL GROWTH HORMONE DEFICIENCY MARKET
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 EXPANSION
- 11.6.2 PRODUCT APPROVAL/FDA APPROVAL

12 COMPANY PROFILES

12.1 MERCK KGAA
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS/SERVICES OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 NOVO NORDISK A/S
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS/SERVICES OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 ELI LILY AND COMPANY
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS/SERVICES OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 F. HOFFMAN LA ROCHE LTD
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS/SERVICES OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 PFIZER, INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS/SERVICES OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 NOVARTIS AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS/SERVICES OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 IPSEN PHARMA
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS/SERVICES OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 FERRING PHARMACEUTICALS
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS/SERVICES OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 SWOT ANALYSIS
- 12.8.6 KEY STRATEGIES
12.9 ANKEBIO CO., LTD
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS/SERVICES OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 SWOT ANALYSIS
- 12.9.6 KEY STRATEGIES
12.10 ZHONGSHAN SINOBIOWAY HYGENE BIOMEDICINE CO., LTD
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS/SERVICES OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES
13.2 RELATED REPORTS